Novartis Expands BeiGene Tie-Up To TIGIT Inhibitor In $1bn-Plus Option Deal

21 Dec 2021

• By Brian Yang

Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.

NOVARTIS EXPANDS COLLABORATION WITH BEIGENE TO TIGIT ANTIBODY IN NEW DEAL • Source: Alamy

More from Deals

More from Business